DOCSLIB.ORG

Comparative Occurance and Population Status of Bird Species in Different Talukas of Patan District (North Gujarat)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparative Occurance and Population Status of Bird Species in Different Talukas of Patan District (North Gujarat) Life Sciences Leaflets FREE DOWNLOAD ISSN 2277-4297(Print) 0976–1098(Online) A REVIEW OF DRUG - INDUCED DIABETES RICHA DODIA AND SUSMITA SAHOO NATUBHAI V. PATEL COLLEGE OF PURE AND APPLIED SCIENCES, CHARUTAR VIDYA MANDAL SINCE 2010 UNIVERSITY, VALLABH VIDYANAGAR, ANAND- 388315, GUJARAT, INDIA. NAAS Rating Corresponding author’s e-mail: [email protected] 2012:1.3; 2013-16: 2.69 2017-2020: 3.98 ABSTRACT: IMPACT FACTOR Drug-induced diabetes is outlined because of the new development of 2019-20: 2.40; 2021:1.09 a hyperglycaemic state that meets the definition of diabetes which is thanks to the consumption of a drug. This medication area unit IPI Value classified in step with the mechanism by that they induce diabetes. The 1.92 primary cluster interferes with insulin resistance and insulin Received on: deficiency, the second interferes with insulin deficiency, the third 25th March 2021 cluster interferes with insulin resistance, and the fourth cluster Revised on: 1st April 2021 interferes with medication that destroys beta cells. Accepted on: 10th April 2021 KEYWORDS: Drug-induced diabetes, Insulin resistance, Insulin Published on: deficiency, Drugs that destroy beta Insulin resistance. 1st June 2021 INTRODUCTION: Volume No. Drug-induced diabetes is the utilization of a selected medication has Online & Print 135-136 (2021) causes the event of diabetes [1]. In some cases, the event of diabetes could also be reversible if the utilization of the medication is Page No. interrupted, however, in different cases, drug-induced diabetes could 01 to 08 Life Sciences Leaflets also be permanent. They act by increasing insulin resistance by is an international open affecting insulin, or both [2]. For convenience, these agents could also access print & e be divided into wide used medication that is weakly diabetic and journal, peer reviewed, worldwide abstract medicines used for special indications that have a lot of powerful listed, published every diabetic properties [3]. month with ISSN, RNI Free- membership, Insulin resistance and insulin deficiency downloads and access. Glucocorticoids https://lifesciencesleaflets.petsd.org/ PEER-REVIEWED Page | 1 Life Sciences Leaflets FREE DOWNLOAD ISSN 2277-4297(Print) 0976–1098(Online) The use of Glucocorticoids is for the treatment of inflammatory things and autoimmune diseases [4]. Diabetes and polygenic disorder are adverse effects of Glucocorticoids, diabetes-induced through Glucocorticoids is conjointly called steroid diabetes, and even hyperglycaemic hyperosmolar nonketotic coma secondary to corticosteroid use has been reported [5].Mechanism of Glucocorticoid-induced hyperglycemia is reduced insulin sensitivity. Steroids excite internal organ hepatic production and stop peripheral aldohexose uptake in muscle and fatty tissue, beyond insulin resistance. More modern studies have urged injurious effects of Glucocortids on pancreatic beta cells, foremost to reduced insulin production [6]. Initial recognition and applicable proactive management of Glucocorticoid-induced hyperglycemia measure are extremely urged. Patients on long-term glucocorticoid treatment and even patients on transient glucocorticoid treatment should be monitored at regular intervals [7]. Among lifestyle dealings, hypoglycaemic medicine with vital insulin sensitizer affects sensitizer indicated, additional oral hypoglycaemic medicine or insulin medical aid can be thought of as the second drug of choice. The initial consistent approach to glucocorticoid‐ induced diabetes is to minimize the glucocorticoid dose to the maximum amount possible. There are few studies of optimum medical treatment for glucocorticoid‐ induced diabetes [8]. Troglitazone has been given to progress postprandial glucose excursions that are the lower area beneath the glucose curve in an oral glucose tolerance test, decrease Glycated hemoglobin (A1C) test, decrease low‐ density lipoprotein, and increase insulin secretion in patients on chronic glucocorticoid,[9] It is suggested to cause side effects like weight gain, heart failure, and bone fractures, entirely of which can be additive to parallel side effects of glucocorticoids in America, the drug was removed from the shop in 2000. There are rare studies of the antidiabetic drug in glucocorticoid diabetes, and it's not ordinarily been suggested as various patients taking glucocorticoid have nephropathy or is also at risk of acidosis pathology, which constitutes contraindications to metformin [10]. The agreement is that blood sugar systematically over 200 mg/dL is related to glucocorticoid therapy should be treated with insulin [10]. Nicotinic acid Nicotinic acid conjointly referred to as niacin, could be a B vitamin prompt for dealing with dyslipidemia [11]. Nicotinic acid is used to treat dyslipidemia, is conversant to cause hyperglycemia that informed severe, though no such effect was discovered in an exceedingly trial in people with diabetes. Its analog, acipimox, doesn't have adverse effects on glycemic management in people with diabetes [12] within the latest analysis study investigates the consequences of niacin on plasma aldohexose, insulin, conjointly C-peptide stages in inactive nondiabetic biological time females, there was a big increase in mean glucose values following niacin medical aid [13]. Niacin-induced hyperglycemia is often associated with high doses, pre- https://lifesciencesleaflets.petsd.org/ PEER-REVIEWED Page | 2 Life Sciences Leaflets FREE DOWNLOAD ISSN 2277-4297(Print) 0976–1098(Online) diabetes, or diabetes. Also, aging is among the danger factors for hyperglycemia throughout niacin medical aid [14]. The lipid‐ lowing drug, nicotinic acid, has long been acknowledged to lift blood sugar and hemoglobin A1C in patients with diabetes [15]. Statin Statins have an association through new-onset diabetes and conveys a Food and Drug Administration warning to this impact. Patients with baseline impaired glucose tolerance who started on statins had a statistically important hour of 1.32 for the event of diabetes [16]. Much statin‐ associated diabetes shows an odd ratio of about one.1 for the development of diabetes once taking statin for up to five years compared to placebo [17]. Hypotheses concerning the mechanism contain inhibition of insulin release through attenuated glucose communication within the beta-cell either or each multiplied beta-cell caspase-mediated cell death and diminished insulin sensitivity of muscle through the diminished expression of the glucose transporter, Glucose transporter type 4. Statins might induce insulin resistance through the suppression of adiponectin. There's proof that the magnitude of those effects varies from medicament to medicament, however, everyone has been related to a little increase in diabetes risk [17]. Insulin deficiency Calcineurin inhibitors Calcineurin inhibitor‐ associated diabetes capability is at first affected by the thought of changing from tacrolimus to cyclosporin A. There are few studies of medical aid for calcineurin inhibitor‐ associated diabetes and skilled opinion suggests that antidiabetic, Glucagon-Like Peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors ought to be explored[18]. Insulin medical aid ought to be introduced if further therapies don't management blood sugar. Calcineurin inhibitors are immunosuppressants that are typically used post‐ transplant to block nuclear factors of activated t cells induction of interleukin‐ 2 manufacture in lymphocytes [19]. Diazoxide Diazoxide is a non - diuretic benzothiadiazole by-product through potent vasodilator properties that was to treat hypertensive crises; it's currently occasionally used for this indication however is verificatory in cases of inoperable insulinoma and to treat profound hypoglycemia succeeding in antidiabetic overdose. The dose used for the treatment of patients through insulinoma ranges between 100 and 600 mg/day, repeatedly in separated doses [20]. Diazoxide could be a non- diuretic benzothiadiazole by-product that will increase the plasma concentration of glucose by decreasing insulin secretion through the gap of potassium or Adenosine Triphosphate channels https://lifesciencesleaflets.petsd.org/ PEER-REVIEWED Page | 3 Life Sciences Leaflets FREE DOWNLOAD ISSN 2277-4297(Print) 0976–1098(Online) within the membranes of exocrine gland beta cells and increasing the hepatic output of glucose [21]. Didanosine Didanosine antiretroviral reverse transcriptase substance nucleoside agonist can trigger pancreatitis in order the ready to patients and a few can have a consequent beta-cell injury. The didanosine-associated symptom has been postulated to decrease insulin secretion within the absence of pancreatitis [22]. Pentamidine Pentamidine seems to own a multiphasic impact on the beta-cell. Initially, the drug causes acute cytolysis and degranulation of beta-cells with the discharge of insulin and hypoglycemia. Later on, beta-cell destruction and impaired insulin release develop with the onset of hyperglycemia and even public diabetic ketoacidosis might occur at intervals a pair of – 6 months in up to 20 patients [23]. The anti-protozoal drug pentamidine has been used a lot in recent years as a result of its effectiveness in treating the infection with Pneumocystis carinii, as happens in patients with acquired immune deficiency. The drug will cause pancreatitis with low, normal, or raised blood glucose concentration [24] Patients with acquired immunodeficiency syndrome normally suffer from hypoglycemia throughout pentamidine treatment. In
Load more

Recommended publications
  • Safety and Efficacy of Metformin for Therapy-Induced Hyperglycemia in Children with Acute Lymphoblastic Leukemia
    ORIGINAL ARTICLE Safety and Efficacy of Metformin for Therapy-induced Hyperglycemia in Children With Acute Lymphoblastic Leukemia Bruce Bostrom, MD,* Priya Uppal, BA,* Julie Chu, MD,* Yoav Messinger, MD,* Laura Gandrud, MD,w and Robert McEvoy, MDw insulin secretion in response to hyperglycemia and possibly Background: Hyperglycemia during corticosteroid and aspar- reduced number of insulin receptors from asparaginase.2,3 aginase therapy for acute lymphoblastic leukemia is a significant Treatment with either single agent corticosteroids or sin- side effect that is usually treated with insulin. Metformin is an oral gle agent asparaginase causes significant hyperglycemia in antidiabetic biguanide that may cause metabolic acidosis and liver about 1% of patients and the combination synergistically enzyme abnormalities of possible concern in patients receiving chemotherapy. increases glucose intolerance. Risk factors for hyperglycemia included age over 10 years, Down syndrome, obesity, and a Procedure: We reviewed patients with acute lymphoblastic leuke- family history of diabetes mellitus. The frequency of hyper- mia treated with corticosteroids and asparaginase who received glycemia increases when there is >1 risk factor.1 Pui et al metformin for control of hyperglycemia. observed hyperglycemia during remission induction in 41 Results: Seventeen patients received metformin, including 4 who (9.7%) of 421 pediatric patients who received the combination received insulin before starting metformin therapy. Twelve were of prednisone and asparaginase for ALL.4 In 39 of the 41 treated during initial induction therapy and 5 during relapse rein- patients, hyperglycemia developed within a week of the first duction. Corticosteroids included dexamethasone in 11, prednisone dose of asparaginase. Koltin et al5 observed a 15.7% incidence in 5, and megesterol in 1.
    [Show full text]
  • Feline Diabetes Mellitus
    Feline diabetes mellitus Aspects on epidemiology and pathogenesis Malin Öhlund Faculty of Veterinary Medicine and Animal Science Department of Clinical Sciences Uppsala Doctoral thesis Swedish University of Agricultural Sciences Uppsala 2017 Acta Universitatis agriculturae Sueciae 2017:88 Cover: Portrait of a cat and a rat (Photo: S. Yuliia, photo ID 601890158, Shutterstock) ISSN 1652-6880 ISBN (print version) 978-91-7760-066-4 ISBN (electronic version) 978-91-7760-067-1 © 2017 Malin Öhlund, Uppsala Print: SLU Service/Repro, Uppsala 2017 Feline diabetes mellitus. Aspects on epidemiology and pathogenesis Abstract Feline diabetes mellitus (DM) is strikingly similar to human type 2 diabetes. Cats and humans share many risk factors for the disease, including an association with insulin resistance coupled to obesity and a sedentary lifestyle. There are also pathophysiological resemblances, with β-cell loss and amyloid deposition in the islets of Langerhans in the pancreas. In people, ethnicity has been associated with an increased risk of DM, and in cats, a breed predisposition has been identified, with the Burmese breed at increased risk. The aims of this thesis were to identify risk factors for DM in cats and to increase under- standing of disease pathogenesis. We used insurance data from Agria Pet Insurance to determine the general incidence of DM in Swedish cats, and the incidence in relation to age, sex and breed. We found that incidence rates peaked when cats were 13 years old. Male cats developed DM twice as often as female cats. The Burmese breed, along with the Russian Blue, Abyssinian, and Norwegian Forest cat breeds, showed an increased risk of DM, while several breeds showed a lower risk.
    [Show full text]
  • 11Β-HSD1 Plays a Critical Role in Trabecular Bone Loss Associated with Systemic Glucocorticoid Therapy C
    Fenton et al. Arthritis Research & Therapy (2019) 21:188 https://doi.org/10.1186/s13075-019-1972-1 RESEARCH ARTICLE Open Access 11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy C. G. Fenton1,2, C. L. Doig1, S. Fareed2, A. Naylor1, A. P. Morrell3, O. Addison4,5, C. Wehmeyer1, C. D. Buckley1, M. S. Cooper6, G. G. Lavery2, K. Raza1,7 and R. S. Hardy1,2* Abstract Background: Despite their efficacy in the treatment of chronic inflammation, the prolonged application of therapeutic glucocorticoids (GCs) is limited by significant systemic side effects including glucocorticoid-induced osteoporosis (GIOP). 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a bi-directional enzyme that primarily activates GCs in vivo, regulating tissue-specific exposure to active GC. We aimed to determine the contribution of 11β-HSD1 to GIOP. Methods: Wild type (WT) and 11β-HSD1 knockout (KO) mice were treated with corticosterone (100 μg/ml, 0.66% ethanol) or vehicle (0.66% ethanol) in drinking water over 4 weeks (six animals per group). Bone parameters were assessed by micro-CT, sub-micron absorption tomography and serum markers of bone metabolism. Osteoblast and osteoclast gene expression was assessed by quantitative RT-PCR. Results: Wild type mice receiving corticosterone developed marked trabecular bone loss with reduced bone volume to tissue volume (BV/TV), trabecular thickness (Tb.Th) and trabecular number (Tb.N). Histomorphometric analysis revealed a dramatic reduction in osteoblast numbers. This was matched by a significant reduction in the serum marker of osteoblast bone formation P1NP and gene expression of the osteoblast markers Alp and Bglap.In contrast, 11β-HSD1 KO mice receiving corticosterone demonstrated almost complete protection from trabecular bone loss, with partial protection from the decrease in osteoblast numbers and markers of bone formation relative to WT counterparts receiving corticosterone.
    [Show full text]
  • Steroid Induced Diabetes Mellitus in Patients Receiving Prednisolone for Haematological Disorders
    Steroid induced diabetes mellitus in patients receiving prednisolone for haematological disorders Kotila TR1, Olutogun T1, *Ipadeola A2 1. Department of Haematology, College of Medicine, University of Ibadan, Ibadan, Nigeria 2. Department of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria Abstract Introduction: Steroids are a useful component of combination chemotherapy or as a single agent in the treatment of haematological disorders even though there are adverse effects associated with its use. Methods: We report four patients who developed diabetes mellitus (DM) during treatment with steroids for haematological disorders despite a negative history of DM. Results: The mean age of the patients was 55yrs and DM was diagnosed by fasting plasma glucose (FPG) after a cumulative steroid dose of 500-1800mg. Conclusion: It is necessary to have a baseline and frequent FPG in patients who are considered for combination chemotherapy which include steroid since the development of DM does not appear to be dose dependent or related to history of DM in the patient or family. Key words: Steroid, Diabetes Mellitus, Haematological malignancy, Chemotherapy, Adverse effect African Health Sciences 2013; 13(3): 842 - 844 http://dx.doi.org/10.4314/ahs.v13i3.45 Introduction Combination chemotherapy is useful in the glucose tolerance, there are reports on these adverse management of haematological malignancies and this effects in its use in the treatment of many disease evolved from the use of single agents in order to conditions4-6 but we are not aware of any report on overcome drug resistance. Attention was drawn to the side effects of steroids in combination the benefit of steroids in the treatment of lymphoid chemotherapy for haematological disorders.
    [Show full text]
  • Systemic Corticosteroid Therapy—Side Evects and Their Management
    704 Br J Ophthalmol 1998;82:704–708 PERSPECTIVE Br J Ophthalmol: first published as 10.1136/bjo.82.6.704 on 1 June 1998. Downloaded from Systemic corticosteroid therapy—side eVects and their management Rosalyn M Stanbury, Elizabeth M Graham Corticosteroids have been used in ophthalmology for Haematological almost 50 years. Hench, in 1949,1 was the first to report on Polycythaemia is a feature of Cushing’s syndrome but does the beneficial eVects of ACTH and cortisone. His work not appear to be a feature of corticosteroid therapy. was with rheumatoid arthritis and since 1929 he had The total white blood count is increased in patients on noticed that rheumatoid arthritis improved in pregnancy corticosteroids. The various classes of white blood cells are and jaundice. He conjectured that an adrenal hormone aVected in the following ways: might be the common agent causing this improvement. In + Polymorphonuclear leucocytes increased 1948 he managed to acquire the necessary hormones and + Lymphocytes decreased; T cells are reduced to a greater found clinical improvement in the rheumatoid arthritis and extent than B cells although immunoglobulin synthesis a reduction of the erythrocyte sedimentation rate on treat- is also decreased4 ment with the hormones and relapse when they were + Monocytes decreased stopped. His article concluded that theoretically these + Eosinophils decreased agents may be of benefit in other conditions which can be Corticosteroid use promotes blood coagulation and relieved by pregnancy and jaundice. Very soon after this alters the patient’s response to anticoagulants and hence steroids were used, both systemically and topically, to treat frequent checks on the extent of anticoagulation are neces- inflammation of the eye.
    [Show full text]
  • Reversal of Corticosteroid-Induced Diabetes Mellitis with Supplemental Chromium
    L Reversal of corticosteroid-induced diabetes mellitis with supplemental chromium A. Ravina*, L. Slezak*, N. Mirsky*, N. A. Bryden² and R. A. Anderson² Abstract *Department of Diabetes, The Linn Clinic, Haifa, Aims To determine if the stress of corticosteroid treatment increases chromium Department of, Biology, Oranim University of (Cr) losses and if corticosteroid-induced diabetes (steroid diabetes) can be reversed Haifa, Israel by supplemental chromium. ² Nutrient Requirements and Functions Laboratory, Beltsville Human Nutrition Research Methods The effects of corticosteroid treatment on chromium losses of 13 patients Center, Beltsville, MD, USA 2 days prior to steroid administration and the ®rst 3 days following treatment were determined. Since steroid-induced diabetes was associated with increased Received 20 May 1998; revised 3 August 1998; accepted 18 August 1998 chromium losses and insuf®cient dietary chromium is associated with glucose intolerance and diabetes, we treated three patients with steroid-induced diabetes with 600 mg per day of chromium as chromium picolinate. Results Urinary chromium losses following corticosteroid treatment increased from 155 6 28 ng/d before corticosteroid treatment to 244 6 33 ng/d in the ®rst 3 days following treatment. Chromium supplementation of patients with steroid- induced diabetes resulted in decreases in fasting blood glucose values from greater than 13.9 mmol/l (250 mg/dl) to less than 8.3 mmol/l (150 mg/dl). Hypoglycaemic drugs were also reduced 50% in all patients when given supplemental chromium. Conclusions These data demonstrate that corticosteroid treatment increases chromium losses and that steroid-induced diabetes can be reversed by chromium supplementation. Follow-up, double-blind studies are needed to con®rm these observations.
    [Show full text]
  • Incidence and Risk Factors of Steroid-Induced Diabetes in Patients with Respiratory Disease
    ORIGINAL ARTICLE Respiratory Diseases DOI: 10.3346/jkms.2011.26.2.264 • J Korean Med Sci 2011; 26: 264-267 Incidence and Risk Factors of Steroid-induced Diabetes in Patients with Respiratory Disease Seo Yun Kim1, Chul-Gyu Yoo1, Glucocorticoids are effective for treating several respiratory diseases. However, they can Chun Taeg Lee2, Hee Soon Chung3, cause hyperglycemia. This study determined the incidence and risk factors of steroid- Young Whan Kim1, Sung Koo Han1, induced diabetes mellitus (S-DM) in patients treated with glucocorticoid for respiratory Young-Soo Shim1, and Jae-Joon Yim1 diseases. A retrospective study examined patients with respiratory diseases treated with a prednisolone-equivalent glucocorticoid dose exceeding 20 mg/day for at least 4 weeks 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute between January 2003 and December 2008. Patients whose initial random glucose level of Medical Research Center, Seoul National exceeded 200 mg/dL or who had pre-existing diabetes were excluded. S-DM was defined University College of Medicine, Seoul; 2Division of as a fasting glucose concentration exceeding 126 mg/dL or a random glucose concentration Pulmonary and Critical Care Medicine, Department exceeding 200 mg/dL at least twice after beginning steroid treatment. A total of 231 of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University Bundang patients with respiratory diseases met the inclusion criteria. Their median age was 55 yr, Hospital, Seongnam; 3Division of Pulmonary and and 139 were female. The median cumulative prednisolone-equivalent glucocorticoid dose Critical Care Medicine, Department of Internal was 4,965 mg, and the median duration of steroid treatment was 193 days.
    [Show full text]
  • Empagliflozin Compared to NPH Insulin for Steroid Diabetes
    Klarskov et al. BMC Endocrine Disorders (2020) 20:86 https://doi.org/10.1186/s12902-020-00561-0 STUDY PROTOCOL Open Access Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment Carina Kirstine Klarskov1* , Helga Holm Schultz2, Frederik Persson3, Tomas Møller Christensen4, Thomas Peter Almdal5, Ole Snorgaard6, Katrine Bagge Hansen3, Ulrik Pedersen-Bjergaard1,7 and Peter Lommer Kristensen1 Abstract Background: A well-known metabolic side effect from treatment with glucocorticoids is glucocorticoid-induced diabetes mellitus (GIDM). Guidelines on the management of GIDM in hospitalized patients (in the non-critical care setting), recommend initiation of insulin therapy. The scientific basis and evidence for superiority of insulin therapy over other glucose lowering therapies is however poor and associated with episodes of both hypo- and hyperglycaemia. There is an unmet need for an easier, safe and convenient therapy for glucocorticoid-induced diabetes. Methods: EANITIATE is a Danish, open, prospective, multicenter, randomized (1:1), parallel group study in patients with new-onset diabetes following treatment with glucocorticoids (> 20 mg equivalent prednisolone dose/day) with blinded endpoint evaluation (PROBE design). Included patients are randomized to either a Sodium-Glucose- Cotransporter 2 (SGLT2) inhibitor or neutral protamin Hagedorn (NPH) insulin and followed for 30 days. Blinded (Continued on next page) * Correspondence: [email protected] 1Department of Endocrinology and Nephrology, Nordsjaellands Hospital, Dyrehavevej 29, DK-3400 Hilleroed, Denmark Full list of author information is available at the end of the article © The Author(s).
    [Show full text]
  • Adrenocortical Hormones BIMM118 Adrenocortical Hormones
    Steroid-based Drugs • Adrenocortical Hormones BIMM118 Adrenocortical Hormones Adrenal gland: • Medulla: – produces Epinephrine (stimulated by sympathetic impulse) • Cortex: – Zona glomerulosa – produces Aldosterone (stimulated by Angiotensin II and ACTH) – Zona fasciculata – produces Glucocorticoids (stimulated by ACTH = Corticotropin) – Zona reticularis – produces Androgens (physiological role unclear) BIMM118 Adrenocortical Hormones Steroid hormone synthesis: • Pregnenolone synthesis is rate-limiting step • C21 hydroxylase: – Prevents hydroxylation of C17 (-> c) => Only mineralocorticoids • C17 hydroxylase: – Hydroxylation of C17 (-> f, g) can be followed by hydroxylation of C11 and C21 (-> h, j, k) => Sex hormones and glucocorticoids • P450C17α hydroxylase: – Produces 17-Keto-steroids (-> l) => Sex hormones BIMM118 Adrenocortical Hormones Steroid hormone classification: • Progesterone: – C21 – C 3: =O – C17: -OH or =O • Mineralocorticoids: – C21 – C21: -OH – C3: =O • Glucocorticoids : – C21 – C21, C17: -OH – C 3: =O – C11: -OH or =O • Estrogens : – C18 – C17: -OH or =O – C 3: -OH • Androgens : – C19 – C17: -OH – C 3: =O BIMM118 Adrenocortical Hormones Glucocorticoids (GC): • Inhibit all phases of inflammatory reaction • Promote fetal development (lungs) • Inhibit NFκB nuclear translocation => transcription of proinflammatory mediators is prevented • Upregulate lipocortin => inhibits PLA2 => no PG and LT synthesis • Undesirable effects of increased GC: – Immune suppression – Increased glucose release (=> “steroid diabetes”) – Glucose
    [Show full text]
  • Investigation and Management of Steroid Diabetes
    Diabetes Clinical Guideline INVESTIGATION AND MANAGEMENT OF STEROID DIABETES SETTING Oxford Children’s Hospital. Oxford University Hospitals Trust FOR STAFF Clinical staff in the Paediatric Haematology/Oncology departments, and others _____________________________________________________________________________ GUIDANCE This guidance is recommended for use by staff looking after children with or at risk of Steroid Induced Diabetes, for example oncology patients. We recommend that the ward staff monitor and commence treatment according to the following guidelines, but also contact the diabetes team via the registrar (bleep 1775) to inform them of the patient details at an early stage. The diabetes specialist nurses should also be contacted to arrange teaching for the patient and family regarding injections and blood glucose (BG) monitoring (telephone 28737 or 28736). Out of hours and at weekends (but not in the middle of the night) please telephone the out of hours mobile 07823 533466. DIAGNOSING STEROID DIABETES (S-DM): There are no clear guidelines in the literature about the timing or diagnosis of S-DM. It is known that S- DM can start at any point after commencing steroid treatment, and is more likely in the first week of treatment with high-dose steroid protocols. Studies have also shown that steroids affect post-prandial BG levels more than fasting levels. It is therefore important to measure BG levels through-out the day in addition to fasting levels. RECOMMENDATIONS for DIAGNOSIS: All children on high-dose steroid treatment should have BG levels monitored. Fasting BG and pre-evening meal BG levels should be measured twice a day. If not feasible in an individual patient, glucose in the urine will indicate whether the threshold of around 10 mmol/l has been reached and after that BG levels should be monitored.
    [Show full text]
  • Serum Lipid Levels During Oral Contraceptive and Glucocorticoid Administration'
    J. clin. Path., 23, suppl. (Ass. Clin. Path.), 3, 55-61 Serum lipid levels during oral contraceptive and glucocorticoid administration' J. W. H. DOAR AND V. WYNN From the Alexander Simpson Laboratory for Metabolic Research, St Mary's Hospital Medical School, London SYNOPSIS The effects of oral contraceptives on fasting serum lipid levels have been studied longitudinally in two groups of women. One hundred and twenty-eight subjects (group A) were tested before and during therapy; 52 subjects (group B) were tested initially during therapy and again after this had been discontinued. In both groups oral contraceptive therapy was associated with significantly raised mean serum triglyceride and cholesterol levels. No relation was found between the magnitude of change of serum triglyceride levels and the nature of oestrogen-progestogen combination, age, parity, degree of obesity, family history of diabetes, or duration of therapy. A significant elevation of the mean fasting serum triglyceride level was also found in a group of 19 women receiving low-dose glucocorticoid therapy, though the percentage increase (16%) was less than that in the wemen receiving oral contra- ceptives (49 %). Studies carried out in the decade 1950-59 showed that the relative impairment of oral glucose that oestrogen therapy was associated with a tolerance commonly found during oral contra- reduction in serum cholesterol and low density ceptive therapy is 'steroid diabetes' (Wynn et al, lipoprotein levels in postmenopausal women and 1966, 1969) caused by elevation of both the free men, many of whom had ischaemic heart disease and protein-bound plasma cortisol levels (Burke, (Russ, Eder, and Barr, 1951; Oliver and Boyd, 1969).
    [Show full text]
  • Implications for Glucose Homeostasis, Insulin Resistance and Diabetes
    ARAFACHO and others Glucocorticoids and pancreatic 223:3 R49–R62 Review endocrine cells Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes Alex Rafacho1, Henrik Ortsa¨ter2, Angel Nadal3 and Ivan Quesada3 Correspondence 1Department of Physiological Sciences, Center of Biological Sciences, Federal University of Santa Catarina (UFSC), should be addressed 88040-900, Floriano´ polis, SC, Brazil to A Rafacho or I Quesada 2Department of Clinical Science and Education, So¨ dersjukhuset, Karolinska Institutet, SE-11883 Stockholm, Sweden Emails 3Institute of Bioengineering and the Biomedical Research Center in Diabetes and Associated Metabolic Disorders [email protected] or (CIBERDEM), Miguel Herna´ ndez University, University Avenue s/n, 03202, Elche, Spain [email protected] Abstract Glucocorticoids (GCs) are broadly prescribed for numerous pathological conditions because Key Words of their anti-inflammatory, antiallergic and immunosuppressive effects, among other " glucocorticoids actions. Nevertheless, GCs can produce undesired diabetogenic side effects through " insulin resistance interactions with the regulation of glucose homeostasis. Under conditions of excess and/or " insulin sensitivity long-term treatment, GCs can induce peripheral insulin resistance (IR) by impairing insulin " insulin secretion Journal of Endocrinology signalling, which results in reduced glucose disposal and augmented endogenous glucose " glucagon secretion production. In addition, GCs can promote abdominal obesity, elevate plasma fatty acids and " glucose tolerance triglycerides, and suppress osteocalcin synthesis in bone tissue. In response to GC-induced " diabetes peripheral IR and in an attempt to maintain normoglycaemia, pancreatic b-cells undergo several morphofunctional adaptations that result in hyperinsulinaemia. Failure of b-cells to compensate for this situation favours glucose homeostasis disruption, which can result in hyperglycaemia, particularly in susceptible individuals.
    [Show full text]